TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$82 Million

Cascadian Therapeutics

Follow-on Offering

Lead Left Bookrunner, January 2017

Confidentially Marketed Public Offering

Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Its lead clinical-stage product candidate is tucatinib, an orally active and selective small-molecule HER2 inhibitor. The Company is also developing preclinical product candidates in oncology using its Chk1 kinase inhibitor CASC 578 and its protocell technology. Tucatinib is a selective small molecule inhibitor of HER2, also known as ErbB2, a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers, such as gastric and ovarian cancer. The Company is developing tucatinib for the treatment of HER2-positive (HER2+) metastatic breast cancer.